Hanieh Noormohamadi

Hanieh Noormohamadi

Auto-generated profile, based on publicly available information

Hanieh Noormohamadi

Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
HSHamed soleimani samarkhazan
Hamed soleimani samarkhazan
FSFatemeh Sadat Shafiei
Fatemeh Sadat Shafiei
ZTZahra Taghinejad
Zahra Taghinejad
MMMohsen Maleknia
Mohsen Maleknia
HNHanieh Noormohamadi
Hanieh Noormohamadi
SNSina Nouri
Sina Nouri
Acute myeloid leukemia (AML) remains a high-mortality cancer due to its aggressive nature and immunosuppressive tumor microenvironment (TME), which enables evasion of immune surveillance. Despite chemotherapy and targeted therapies, 5-year survival is ~ 30%, necessitating novel immunotherapies. AML suppresses cytotoxic T/NK cells by co-opting regulatory pathways, creating an “immune paradox.” Emerging strategies aim to disrupt this evasion. Immune checkpoint inhibitors (ICIs), such as anti-PD-1 nivolumab and anti-CD47 magrolimab, combined with hypomethylating agents (HMAs), enhance T-cell activity and phagocytosis, especially in TP53-mutated AML. Therapeutic vaccines targeting leukemia-associated antigens (e.g., WT1, PRAME) via dendritic cell fusion show early success in prolonging remission. Combinatorial approaches, like HMAs with STING agonists or dual checkpoint blockade, target multiple immunosuppressive pathways to overcome resistance. Challenges include TME heterogeneity, therapy-resistant leukemia stem cells, toxicities (e.g., anemia, cytokine release syndrome), relapse from clonal evolution, and a lack of predictive biomarkers. Autologous therapies face economic and logistical hurdles, driving demand for scalable solutions. Advances in single-cell genomics, AI, and synthetic biology are identifying novel targets (TIM-3, TIGIT, VISTA) and improving patient stratification. Integrating these innovations may transform AML into a chronic condition, bridging preclinical potential to clinical impact. In this review, we aim to evaluate mechanisms, challenges, and future directions of immunotherapies in AML with highlighting ICIs and vaccination to improve therapeutic outcomes.

24 June 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
HSHamed soleimani samarkhazan
Hamed soleimani samarkhazan
HNHanieh Noormohamadi
Hanieh Noormohamadi
FSFatemeh Sadat Shafiei
Fatemeh Sadat Shafiei
ZTZahra Taghinejad
Zahra Taghinejad
MMMohsen Maleknia
Mohsen Maleknia
MMmohammad hossein Mohammadi
mohammad hossein Mohammadi
Acute myeloid leukemia (AML), a heterogeneous and aggressive hematologic malignancy, remains challenging to treat due to high relapse rates, chemotherapy resistance, and the immunosuppressive tumor microenvironment (TME). While traditional therapies like chemotherapy and hematopoietic stem cell transplantation have improved outcomes, their efficacy is often limited by toxicity and disease recurrence. Recent advancements in antibody engineering have revolutionized AML immunotherapy, offering precision-targeted strategies to overcome these barriers. This narrative review explores the transformative role of monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and bispecific antibodies (bsAbs) in redirecting immune effector cells, blocking immune checkpoints, and eradicating leukemic stem cells (LSCs). Key innovations include CD33-targeted gemtuzumab ozogamicin, CD123-directed bispecific engagers, and anti-CD47 agents that disrupt "don't eat me" signals. We highlight breakthroughs in antibody design-such as Fc optimization, trispecific constructs, and conditionally active biologics-that enhance specificity while minimizing on-target off-tumor toxicity. Clinical trials demonstrate promising results, including improved remission rates and survival in refractory/relapsed AML when combining antibodies with hypomethylating agents, venetoclax, or checkpoint inhibitors. However, challenges persist, including AML's genetic heterogeneity, adaptive immune evasion, and cytokine release syndrome (CRS) risks. Emerging strategies such as biomarker-driven personalization, TME modulation, and engineered NK-cell engagers are poised to address these limitations. By integrating preclinical insights with clinical data, this review underscores the potential of antibody-based combinatorial regimens to redefine AML therapy, offering durable responses and bridging the gap to curative approaches.

23 October 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HWHuichao Wu
Huichao Wu
FSFatemeh Sadat Shafiei
Fatemeh Sadat Shafiei
ZTZahra Taghinejad
Zahra Taghinejad
MMMohsen Maleknia
Mohsen Maleknia
HNHanieh Noormohamadi
Hanieh Noormohamadi
HSHamed soleimani samarkhazan
Hamed soleimani samarkhazan
Acute myeloid leukemia (AML), characterized by aggressive relapse and dismal survival, remains a formidable challenge despite conventional therapies. Chimeric antigen receptor (CAR)-engineered T and natural killer (NK) cells have emerged as groundbreaking immunotherapies, offering targeted eradication of leukemic stem cells (LSCs) and resistant blasts. CAR-T cells, leveraging antigens like CD123 and CD33, demonstrate early clinical success, with complete remission rates up to 66% in refractory/relapsed (R/R) AML. CAR-NK cells complement this approach through inherent tumor surveillance, reduced toxicity, and "off-the-shelf" feasibility. However, barriers such as antigen escape, heterogeneous immunosuppressive microenvironments (including intratumoral microbiota variations), and on-target/off-tumor toxicity persist, limiting durable responses. Innovations in dual-targeting CARs, cytokine-armored constructs, and CRISPR-edited universal cells aim to overcome these hurdles. Emerging strategies integrating checkpoint inhibitors, metabolic modulators, and AI-driven antigen selection promise to enhance efficacy and safety. This review synthesizes the evolving landscape of CAR-T/NK therapies, critically analyzing preclinical breakthroughs, clinical trial outcomes, and persisting challenges. By addressing manufacturing scalability, cost barriers, and long-term safety, cellular immunotherapy holds transformative potential to redefine AML management. As the field advances, interdisciplinary collaboration and biomarker-guided personalization will be pivotal in translating laboratory innovations into life-saving therapies for AML patients.

11 August 2025 in Discover Oncology
Verified
Journal Article
Open access
HNHanieh Noormohamadi
Hanieh Noormohamadi
HSHamed soleimani samarkhazan
Hamed soleimani samarkhazan
MKMaryam Kargar
Maryam Kargar
FMFaezeh Maroufi
Faezeh Maroufi
NSNazli Servatian
Nazli Servatian
FDFatemeh Davami
Fatemeh Davami
Pancreatic cancer is marked by a poor prognosis and an exceptionally high mortality rate, with its aggressive nature contributing to its classification as a highly malignant disease. For effective therapeutic strategies, the development of sophisticated and regulated DNA manipulation methods is essential. Originally part of the prokaryotic immune system, CRISPR/Cas has emerged as a pivotal genome-editing tool with promising applications in pancreatic cancer research and therapy. This gene editing method is known for simplicity, rapid advancement, and superior precision compared to earlier techniques. Its adaptability allows precise gene editing for therapeutic purposes, including oncogene silencing and correction of pathogenic mutations. Additionally, CRISPR-driven gene editing has facilitated the development of pancreatic cancer models, which serve as valuable platforms for drug discovery and personalized treatment strategies, offering deeper insights into the genetic landscape of pancreatic tumors. This article provides an overview of the current applications of CRISPR technology in gene therapy and cancer research, particularly in the context of pancreatic cancer, and lays the foundation for future studies.

29 April 2025 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
AHAhmed Hussein
Ahmed Hussein
ASAmin Solouki
Amin Solouki
NPNiloofar Pilehvari
Niloofar Pilehvari
FCFatemeh Sotudeh Chafi
Fatemeh Sotudeh Chafi
HNHanieh Noormohamadi
Hanieh Noormohamadi
HSHamed soleimani samarkhazan
Hamed soleimani samarkhazan
Recurrent spontaneous abortion (RSA) is a multifactorial condition influenced by genetic, hormonal, immunological, and anatomical factors. Thrombophilia, characterized by a heightened propensity for blood clotting, is a significant contributor to RSA. This review examines the mechanisms connecting thrombosis and RSA, focusing on hypercoagulable states, placental thrombosis, inflammation, and endothelial dysfunction. Genetic and acquired thrombophilic factors, such as factor V Leiden mutation, prothrombin gene mutation, protein C and S deficiencies, antithrombin III deficiency, antiphospholipid syndrome, and hyperhomocysteinemia, are discussed in detail. The diagnosis of thrombophilia in RSA entails a comprehensive clinical evaluation, including the assessment of physical examination, medical history and laboratory investigations, although there is still debate over the need for universal screening. Therapeutic strategies, including anticoagulant and antiplatelet therapies, as well as lifestyle modifications, are tailored to individual risk factors and disease severity. Although anticoagulant therapy demonstrates potential in lowering the risk of miscarriage, additional research is necessary to refine treatment protocols and assess long-term outcomes. This review highlights the need for a nuanced approach to managing thrombophilia-associated RSA, balancing diagnostic precision with therapeutic efficacy to improve reproductive outcomes.

11 June 2025 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
HSHamed soleimani samarkhazan
Hamed soleimani samarkhazan
HNHanieh Noormohamadi
Hanieh Noormohamadi
FSFatemeh Sadat Shafiei
Fatemeh Sadat Shafiei
NPNiloofar Pilehvari
Niloofar Pilehvari
AAAmir Hossein Aghaei
Amir Hossein Aghaei
MSMehrnoosh Shanaki
Mehrnoosh Shanaki